Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives - Summary - MDSpire
Advertisement
Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives
To provide a framework for clinicians on the critical role of gadolinium-based contrast agents (GBCAs) in enhancing the accuracy of diagnosis, staging, and monitoring of head and neck cancers (HNCs).
Key Findings:
MRI is essential for staging and monitoring HNCs, with GBCAs significantly improving tumor delineation and treatment response evaluation, as evidenced by recent studies.
Concerns about GBCAs include nephrogenic systemic fibrosis and gadolinium retention in tissues, necessitating ongoing monitoring.
3D post-contrast T1-weighted imaging offers advantages in spatial resolution and vascular assessment over traditional methods, enhancing diagnostic capabilities.
Dynamic contrast-enhanced MRI (DCE-MRI) provides semiquantitative and quantitative parameters for tumor perfusion assessment, aiding in treatment planning.
Interpretation:
GBCAs play a critical role in enhancing MRI for HNCs, but their use must be balanced with safety considerations and environmental impacts, necessitating ongoing research.
Limitations:
Lack of comprehensive evaluations regarding GBCA usage specifically in HNCs, highlighting the need for targeted studies.
Environmental concerns regarding gadolinium contamination and its long-term effects are still being studied, warranting further investigation.
Conclusion:
GBCAs are vital for effective imaging in HNCs, but ongoing research and guidelines are necessary to ensure their safe and responsible use, particularly in light of emerging safety data.
Analysis of 50 cases shows moderate diagnostic agreement between FNAC and histopathology and identifies pleomorphic adenoma as the most common neoplasm.
